Heghine Khachatryan: Addressing Critical Gaps in Cancer-Associated VTE
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from RPTH Journal on LinkedIn, adding:
”Cancer-associated VTE: an old problem, still unresolved
Despite decades of research, cancer-associated venous thromboembolism (VTE) remains a major cause of morbidity and mortality.
This timely editorial in Research and Practice in Thrombosis and Haemostasis highlights critical gaps—from real-time epidemiologic data to optimal thromboprophylaxis and bleeding risk stratification—and points toward future, cancer-specific solutions.
A strong reminder that prevention, individualized risk assessment, and innovation in anticoagulation must remain a global priority in oncology and hematology.
Editorial by Alok Khorana
Research and Practice in Thrombosis and Haemostasis”
Quoting RPTH Journal‘s post:
”Cancer-associated VTE: an old problem, still unresolved
RPTH Journal Editorial by Alok Khorana
As highlighted by Maiocco et al. in RPTH Journal, it remains puzzling that VTE, a complication of cancer known since the 19th century, continues to heavily burden modern oncology care.
- Cancer patients face a 9- to 20-fold higher risk of VTE, even with contemporary therapies
- In a nationwide US inpatient analysis, 8.1% of cancer-related hospitalizations were complicated by VTE
- VTE remains strongly associated with higher mortality, longer hospital stays, and higher costs
- Despite decades of awareness, robust evidence for inpatient thromboprophylaxis in cancer patients is still lacking
Read the editorial here
Read the study by Giuseppe Maiocco et al here”
Title: The public health impact of cancer-associated venous thromboembolism: looking to the future
Authors: Alok Khorana
Read the Full Editorial on RPTH Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 11, 2026, 16:09ESO: We Are Pleased to Introduce You to The Voice of Stroke Podcast
-
Feb 11, 2026, 16:08Bartosz Hudzik: Clinical Trials to Watch in 2026 – A Cardiovascular Lens
-
Feb 11, 2026, 15:57Alan Nurden: Looking Beyond Bleeding in VWD
-
Feb 11, 2026, 15:56Samin Mohsenian: I Have Successfully Defended My PhD on Rare Bleeding and Coagulation Disorders
-
Feb 11, 2026, 15:52Amaliris Guerra: What’s The Most Effective Way to Evaluate and Select The Right Mentor?
-
Feb 11, 2026, 15:20Alfredo Lourenco: How to Prevent Hemolysis During Blood Collection
-
Feb 11, 2026, 15:12Pradeep Natarajan: The AHA Scientific Statement on Clonal Hematopoiesis and CVD Led by June-Wha Rhee
-
Feb 11, 2026, 14:45Jeff June: Stroke Care Isn’t Broken, It’s Under-Informed
-
Feb 11, 2026, 11:07Nathan Connell: 100 Years of von Willebrand Disease – From the Åland Islands to Precision Care